DeciBio Ventures, a venture capital firm investing in and advising precision medicine start-ups, has invested in a $55 million seed funding round for Replay, led by KKR & Co Inc and OMX Ventures.

Additional participants included ARTIS Ventures, Lansdowne Partners, SALT, and Axial.

As part of DeciBio Ventures’ strategy-heavy and supportive VC model, DeciBio Ventures is also providing Replay with ongoing strategic support.

Replay’s portfolio of next-generation genomic medicine technologies aims to solve the key challenges currently limiting clinical progress, including the need for increased payload capacity and off-the-shelf cell therapies that substantially reduce cost of goods, improve production speed, volume and consistency, and expand the potential for genome engineering.